in this issue
People & Business :: Companies
Lonza Signs Manufacturing Deal with U.S. Biopharma Firm
11:52 PM MST | November 24, 2009 | Deepti Ramesh
Lonza says it has entered into an agreement with biopharmaceutical company Micromet (Bethesda, MD) for the process development and manufacture of Micromet’s blinatumomab, a BiTE antibody for the treatment of various hematologic cancers. Micromet develops novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Lonza will manufacture blinatumomab for clinical trials, under the terms of the deal. In addition, Lonza will develop the commercial scale process and will supply blinatumomab for the market if requested by...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee